GLP-1 agonists demonstrate a significant ability to modulate the gut microbiota composition, which represents a promising strategy for addressing obesity and its associated inflammatory environment and offers hope for newer, more effective therapeutic strategies. The gene discussed is GLP1R; the disease is obesity disorder.